Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy

68Citations
Citations of this article
73Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Leber hereditary optic neuropathy (LHON) is an important cause of mitochondrial blindness among young adults. In this study, we investigated the potential of four quinone analogues (CoQ1, CoQ10, decylubiquinone and idebenone) in compensating for the deleterious effect of the m.11778G>A mitochondrial DNA mutation. The LHON fibroblast cell lines tested exhibited reduced cell growth, impaired mitochondrial bioenergetics and elevated levels of reactive oxygen species (ROS). Idebenone increased ATP production and reduced ROS levels, but the effect was partial and cell-specific. The remaining quinone analogues had variable effects and a negative impact on certain mitochondrial parameters was observed in some cell lines.

Cite

CITATION STYLE

APA

Yu-Wai-Man, P., Soiferman, D., Moore, D. G., Burté, F., & Saada, A. (2017). Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy. Mitochondrion, 36, 36–42. https://doi.org/10.1016/j.mito.2017.01.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free